GRAL — GRAIL Inc. stock price, charts and financials

QT63GRAIL Inc.

GRAIL Inc. (NASDAQ: GRAL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
80.77
+0.82+1.03%
OverviewShort InterestFilings
GRALQT63GRAIL Inc.·NASDAQ
80.77+1.03%
Analyst
Up 1.0% — RBC Capital initiated coverage at Sector Perform, price target $84.
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
VCYT-1.90%$39.80WGS-3.67%$101.10CDNA-0.83%$53.83BLLN-4.29%$105.92SHC-1.16%$18.73RDNT-2.29%$76.00PSNL+1.05%$16.40QGEN-2.37%$43.33
Snapshot
Index-P/E-EPS (ttm)-9.75Insider Own23.82%Shs Outstand42.92MPerf Week5.96%
Market Cap3.47BForward P/E-EPS next Y-10.20Insider Trans-2.40%Shs Float39.29MPerf Month9.21%
Enterprise Value2.69BPEG-EPS next Q-2.51Inst Own-Short Float21.66%Perf Quarter26.72%
Income-391.00MP/S20.88EPS this Y1.27%Inst Trans-Short Ratio12.69Perf Half Y66.64%
Sales166.00MP/B1.36EPS next Y-5.96%ROA-13.77%Short Interest8.51MPerf YTD-5.63%
Book/sh59.25P/C4.02EPS next 5Y-ROE-15.88%52W High118.83 -32.03%Perf Year110.78%
Cash/sh20.09P/FCF-EPS past 3/5Y-ROIC-14.93%52W Low38.89 107.69%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y37.95% -Gross Margin-10.83%Volatility5.92% 5.82%Perf 5Y-
Dividend TTM-EV/Sales16.18EPS Y/Y TTM84.66%Oper. Margin-338.40%ATR (14)4.47Perf 10Y-
Dividend Ex-Date-Quick Ratio10.74Sales Y/Y TTM31.75%Profit Margin-236.95%RSI (14)58.76Recom2.50
Dividend Gr. 3/5Y-Current Ratio10.95EPS Q/Q19.50%SMA202.30%Beta2.59Target Price69.83
Payout0.00%Debt/Eq0.04Sales Q/Q25.00%SMA509.21%Rel Volume4.20Prev Close79.95
Employees910LT Debt/Eq0.03EarningsNov 11SMA20011.81%Avg Volume714.08KPrice80.77
IPO DateJun 12, 2024Option/ShortYes / YesEPS/Sales Surpr.3.60% 5.42%Net Debt/EBITDA-0.09Volume3,002,145Change1.03%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-17-26InitiatedRBC CapitalSector Perform$84
Sep-09-26InitiatedUBSBuy$75 → $105
Jul-15-26ReiteratedMizuhoNeutral$58 → $65
Jun-05-26ReiteratedGoldman Sachs$60
May-06-26ReiteratedRobert W. Baird$82 → $70
May-06-26ReiteratedPiper SandlerNeutral$54 → $56
Apr-10-26InitiatedMizuhoNeutral$58
Apr-10-26InitiatedPiper SandlerNeutral$54
Feb-24-26ReiteratedMorgan StanleyEqual Weight$110 → $60
Feb-20-26ReiteratedRobert W. Baird$113 → $82
Latest News· Times ET
Sep-14-26
Sep-14-2609:41AM
GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha
Sep-09-26
Sep-09-2605:21AM
UBS Initiates Coverage On GRAIL with Buy Rating, Announces Price Target of $105Benzinga
Sep-08-26
Sep-08-2611:53PM
Concurrent Investment Advisors LLC Grows Position in GRAIL, Inc. $GRALdefenseworld.net
06:55PM
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000fool.com
Sep-04-26
Sep-04-2603:50AM
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Testfool.com
Sep-03-26
Sep-03-2612:02PM
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)prnewswire.com
Aug-31-26
Aug-31-2612:01PM
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conferenceprnewswire.com
Aug-20-26
Aug-20-2601:45PM
Hedging Exposure In This Volatile MarketSeekingAlpha
Aug-13-26
Aug-13-2611:04PM
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meetingmarketbeat.com
Aug-12-26
Aug-12-2611:36PM
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRALdefenseworld.net
12:40PM
GRAIL: Looking Beyond The NHS-Galleri Headlineseekingalpha.com
Aug-10-26
Aug-10-2609:30AM
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection TestBenzinga
Aug-07-26
Aug-07-2607:26AM
US FDA to hold advisory meeting to review Grail's multi-cancer testreuters.com
07:05AM
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Testprnewswire.com
Aug-05-26
Aug-05-2608:10PM
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Company

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue166147126——————
Cost of Goods Sold Incl. D&A183210204——————
Gross Profit-18-63-78——————
Selling, General and Administrative Excl. Other290276368——————
Research and Development191196322——————
Other Operating Expense6001,421——————
Operating Income-559-534-2,189——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)30027——————
Net Income Before Taxes-531-535-2,162——————
Income Taxes-137-126-135——————
Consolidated Net Income-391-408-2,027——————
Net Income From Continuing Operations-391-408-2,027——————
Net Income-391-408-2,027——————
EPS (Recurring)-9.75-11.11-63.54——————
EPS (Basic, Before Extraordinaries)-9.75-11.11-63.54——————
EPS (Diluted)-9.75-11.11-63.54——————
EBITDA-414-378-610——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio20.9221.544.53——————
Gross Margin-10.84-42.86-61.90——————
Operating Margin-336.75-363.27-1,737.30——————
Net Margin-235.54-277.55-1,608.73——————
Shares Outstanding433732——————
Market Capitalization3,4733,167571——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$128.76$101.25$73.74$46.23$18.72● Close Price0.00M20.00M39.99M59.99M79.98MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Freidin AaronChief Financial OfficerAug 27 '26Sale85.017,900671,579253,083Aug 31
Ofman Joshua J.Chief Executive OfficerAug 27 '26Sale85.025,000425,098397,271Aug 31
Partridge Andrew JohnChief Growth OfficerJun 04 '26Sale61.081,49191,070163,738Jun 05
Freidin AaronChief Financial OfficerApr 08 '26Sale49.9245,8062,286,526260,669Apr 09
RAGUSA ROBERT PChief Executive OfficerApr 08 '26Sale49.92123,5026,164,923518,582Apr 09
Ofman Joshua J.PresidentApr 08 '26Sale49.9261,6653,078,169371,216Apr 09
RAGUSA ROBERT PChief Executive OfficerMar 09 '26Sale47.897,461357,296642,084Mar 09
Freidin AaronChief Financial OfficerMar 09 '26Sale47.892,492119,341306,475Mar 09
Ofman Joshua J.PresidentMar 09 '26Sale47.892,937140,650432,881Mar 09
Ofman Joshua J.PresidentMar 05 '26Sale53.0169036,577435,818Mar 09
RAGUSA ROBERT PChief Executive OfficerMar 05 '26Sale53.0198051,950649,545Mar 09
Freidin AaronChief Financial OfficerMar 05 '26Sale53.0165534,722308,967Mar 09
Freidin AaronChief Financial OfficerMar 02 '26Sale50.179,573480,244309,622Mar 03
RAGUSA ROBERT PChief Executive OfficerMar 02 '26Sale50.1737,5041,881,417650,525Mar 03
Ofman Joshua J.PresidentMar 02 '26Sale50.1617,002852,848436,508Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.